Factors affecting warfarin therapy following cardiac valve surgery

Annals of Pharmacotherapy

Volumn 36, Issue 12, 2002, Pages 1845-1850

  Lee, Juyeun ^a   Lee, Byungkoo ^a   Kim, Kibong ^a   Ahn, Hyuk ^a   Suh, Okkyung ^b   Lee, Myungkoo ^c   Shin, Wangyoon ^b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c Chungbuk National University   (South Korea)

Author keywords

Anticoagulation response; Cardiac valve; Warfarin

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; WARFARIN;

ADULT; ARTICLE; BLEEDING; DOSE RESPONSE; DRUG INTERACTION; ETHNIC GROUP; FEMALE; HEART VALVE REPLACEMENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; KOREA; MALE; RETROSPECTIVE STUDY; VALVULAR HEART DISEASE; ALBUMIN BLOOD LEVEL; BODY WEIGHT; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; DRUG SENSITIVITY; INTERNATIONAL STANDARD UNIT; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; OPERATION DURATION; PHYSICIAN; PRIORITY JOURNAL; SEX DIFFERENCE;

ADULT; AMIODARONE; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ETHNIC GROUPS; FEMALE; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; KOREA; MALE; RETROSPECTIVE STUDIES; WARFARIN;

EID: 0036894728     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1A431     Document Type: Article

References (27)

1. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complication in patients with mechanical heart valves. Circulation 1994; 89:635-41.
2. Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1998;114(suppl):445S-69S.
3. Turpie AGG. Safer anticoagulation therapy after heart valve replacement. Postgrad Med 1997;101:85-94.
4. Choonara IA, Malia RG, Haynes BP, Hay CR, Cholerton S. Breckenridge AM, et al. The relationship between inhibition of vitamin K 1,2,3-epoxide reductase and reduction of clotting factor activity with warfarin. Br J Clin Pharmacol 1988;25:1-7.
5. Whitlon DS, Sadowski JA, Suttie JW. Mechanisms of coumarin action: Significance of vitamin K epoxide reductase inhibition. Biochemistry 1978;17:1371-7.
6. Holfold NHG. Clinical pharmacokinetics and pharmacodynamics of warfarin: Understanding the dose-effect relationship. Clin Pharmacokinet 1986;11:483-504.
7. Shetty HGM, Fennerty AG, Routledge PA. Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy. Clin Pharmacokinet 1989;16:238-53.
8. O'Reilly RA, Aggeler PM. Studies on coumarin anticoagulant drugs. Initiation of warfarin without a loading dose. Circulation 1968;38:169-77.
9. Ansell JE, Buttaro ML, Thomas OV, Knowlton CH. Consensus guidelines for coordinated outpatient oral anticoagulation therapy management. Anticoagulation Guidelines Task Force. Ann Pharmacother 1997; 31:604-15.
10. Killilea TA, Eugene OR, White R, Colemen RW. Increased response to warfarin in valve replacement patients compared to PE/DVT patients (abstract). Clin Pharmacol Ther 1988;43:161.
11. Rose JP, Rhin TL, Long SF. Warfarin sensitivity after mechanical heart valve replacement. Pharmacotherapy 1998:18:856-9.
12. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001;40:587-603.
13. Chan TYK, Tsoi WC, Critchley JAJH. The determinants of warfarin requirement in Chinese patients. Pharmacoepidemiol Drug Saf 1992;1:281-2.
14. Angaran DM, Dias VC. Arom KV, Northrup WF, Kersten TE, Lindsay WG, et al. The influence of prophylactic antibiotics on the warfarin anticoagulation response in the postoperative prosthetic cardiac valve patient. Ann Surg 1984;199:107-11.
15. Mori F, Nakahara Y, Kurata S, Furukawa S, Esato K, Mohri H. Late changes in hemostatic parameters following open-heart surgery. J Cardiovasc Surg 1982;23:458-62.
16. Gelb AB, Roth RI, Levin J, London MJ, Noall RA, Hauck WW, et al. Changes in blood coagulation during and following cardiopulmonary bypass: Lack of correlation with clinical bleeding. Am J Clin Pathol 1996;160:87-99.
17. Piroli RJ, Passananti GT, Shively CA, Vesell ES. Antipyrine and warfarin disposition in a patient with idiopathic hypoalbuminemia. Clin Pharmacol Ther 1981;30:810-6.
18. Ganeval D, Fischer AM, Barre J, Petruiset N, Dautzenberg D, Jungers P, et al. Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors. Clin Nephrol 1986;25:75-80.
19. Almog S, Shafran N, Halkin H, Weiss P, Farfel Z, Martinowitz U, et al. Mechanism of warfarin potentiation by amiodarone: Dose- and concentration-dependent inhibition of warfarin elimination. Eur J Clin Pharmacol 1985;28:257-61.
20. Kerin NZ, Blevins RD, Goldman L, Faitel K, Rubenfire M. The incidence, magnitude, and time course of the amiodarone-warfarin interaction. Arch Intern Med 1988;148:1779-81.
21. Wynne H, Cope L, Kelly P. Whittingham T, Edwards C, Kamali F. The influence of age, liver size and enantiomer concentrations on warfarin requirements. Br J Clin Pharmacol 1995;40:203-7.
22. James AH, Britt RP, Raskino CL, Thompson SG. Factors affecting the maintenance dose of warfarin. J Clin Pathol 1992;45:704-6.
23. Redwood M, Taylor C, Bain BJ, Matthews JH. The association of age with dosage requirement for warfarin. Age Ageing 1991;20:217-20.
24. Routledge PA, Champman PH, Davis DM, Rawins MD. Factors affecting warfarin requirements. Eur J Clin Pharmacol 1979;15:319-22.
25. Eccles JT. Control of warfarin therapy in the elderly. Age Ageing 1988; 17:401-5.
26. Russmann S, Gohlke-Barwolf C, Jahnchen E, Trenk D, Roskamm H. Age-dependent differences in the anticoagulant effect of phenprocoumon in patients after heart valve surgery. Eur J Clin Pharmacol 1997;52:31-5.
27. Wickramasinghe LSP, Basu SK, Bansal SK. Long term oral anticoagulant therapy in elderly patients. Age Ageing 1988;17:388-96.